You are here

ACC

Rivaroxaban reduces adverse kidney events in atrial fibrillation patients with CKD

Rivaroxaban reduces adverse kidney events in atrial fibrillation patients with CKD

Clinical Trials Arena

real world data

atrial fibrillation

Flag link:

ACC 2023 – the market tries to take Medtronic’s pulse

ACC 2023 – the market tries to take Medtronic’s pulse

EP Vantage

pulsed field ablation

clinical trials

Flag link:

ACC23: J&J's combo pill of Opsumit plus tadalafil improves blood flow in PAH patients

ACC23: J&J's combo pill of Opsumit plus tadalafil improves blood flow in PAH patients

Fierce Pharma

Flag link:

ACC 2023 – Esperion’s outcomes win looks lacklustre

ACC 2023 – Esperion’s outcomes win looks lacklustre

EP Vantage

Esperion Therapeutics

Flag link:

Medtronic self-expanding TAVR shows durability benefit over surgery at 5 years, analysis shows

Medtronic self-expanding TAVR shows durability benefit over surgery at 5 years, analysis shows

Medtech Dive

Flag link:

ACC 2022 – Astra’s cholesterol lowerer surprise comes just a little late

ACC 2022 – Astra’s cholesterol lowerer surprise comes just a little late

EP Vantage

Ionis Pharmaceuticals

Flag link:

ACC: Bayer’s Kerendia cuts cardio and kidney complications in high-risk patients

ACC: Bayer’s Kerendia cuts cardio and kidney complications in high-risk patients

Fierce Pharma

Flag link:

ACC: Lexicon hopes sotagliflozin cardio data will set its drug apart from SGLT2 rivals

ACC: Lexicon hopes sotagliflozin cardio data will set its drug apart from SGLT2 rivals

Fierce Pharma

Lexicon Pharmaceuticals

type 2 diabetes

Flag link:

ACC 2022 – Bristol's rare hit could justify Myokardia

ACC 2022 – Bristol's rare hit could justify Myokardia

EP Vantage

Bristol Myers Squibb

hypertrophic cardiomyopathy

Flag link:

ACC 2021: With Amgen out of the picture, Cytokinetics imagines supporting role for omecamtiv in heart failure

ACC 2021: With Amgen out of the picture, Cytokinetics imagines supporting role for omecamtiv in heart failure

Fierce Biotech

Omecamtiv Mecarbil

Flag link:

Boston Scientific's Watchman shows low stroke rate in large registry at ACC

Boston Scientific's Watchman shows low stroke rate in large registry at ACC

Medtech Dive

Boston Scientific

atrial fibrillation

Flag link:

ACC 2021: J&J, Bayer pad case for Xarelto in post-surgery artery disease patients

ACC 2021: J&J, Bayer pad case for Xarelto in post-surgery artery disease patients

Fierce Pharma

Flag link:

Regeneron's Evkeeza shows promise in curbing high triglycerides, but will genetic disparities limit use?

Regeneron's Evkeeza shows promise in curbing high triglycerides, but will genetic disparities limit use?

Endpoints

high triclycerides

Flag link:

ACC 2021: Novartis looks for silver linings in Entrestro’s narrow loss to an ACE inhibitor in heart attack patients

ACC 2021: Novartis looks for silver linings in Entrestro’s narrow loss to an ACE inhibitor in heart attack patients

Fierce Pharma

Flag link:

ACC: New owner Novartis presents pooled inclisiran data cutting LDL cholesterol by half

ACC: New owner Novartis presents pooled inclisiran data cutting LDL cholesterol by half

Fierce Biotech

PCSK9 inhibitors

Flag link:

ACC: Esperion's Nexletol busts cholesterol levels regardless of statin, ezitimibe therapy

ACC: Esperion's Nexletol busts cholesterol levels regardless of statin, ezitimibe therapy

Fierce Pharma

clinical trials

c-reactive protein

Flag link:

ACC: Amgen's Repatha cuts cholesterol in rarely studied HIV patients

ACC: Amgen's Repatha cuts cholesterol in rarely studied HIV patients

Fierce Pharma

clinical trials

Flag link:

ACC: J&J, Bayer's blood thinner Xarelto scores in artery disease post-surgery

ACC: J&J, Bayer's blood thinner Xarelto scores in artery disease post-surgery

Fierce Pharma

clinical trials

peripheral artery disease

Flag link:

ACC: Bayer and Merck’s vericiguat leads off virtual meeting with positive phase 3 heart failure data

ACC: Bayer and Merck’s vericiguat leads off virtual meeting with positive phase 3 heart failure data

Fierce Biotech

clinical trials

Flag link:

Even More Conferences Canceled Over Coronavirus Concerns

Even More Conferences Canceled Over Coronavirus Concerns

Medical Devices and Diagnostics Industry

Flag link:

Pages